Randomized controlled trial of interferon-beta-1a in secondary progressive MS

Li, D. K.B.; Zhao, Guojun; Paty, Donald W.

doi:10.1212/wnl.56.11.1505

Cited by 281 publications

(94 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the last decade, a number of immunomodulatory and immunosuppressive therapies have been approved for clinical use based primarily on demonstration of their ability to suppress focal inflammatory activity, i.e., lesion formation, and clinical relapses (Comi et al, 2001;Leary et al, 2003;Li and Paty, 1999;Li et al, 2001;Miller et al, 1999;Paty and Li, 1993;Simon et al, 1998;Simon et al, 2000;Zhao et al, 2000). Development of these therapies has been critically dependent on MRI because of the ability of MRI to visualize lesion formation with an order of magnitude greater sensitivity than clinical observation is able to detect relapses The number and volume of MS lesions represent the "burden of disease" and are predictive of patients' clinical course over the long term (O'Riordan et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

García-Lorenzo

Francis

Narayanan

et al. 2013

Medical Image Analysis

316

268

View full text Add to dashboard Cite

Magnetic resonance (MR) imaging is often used to characterize and quantify multiple sclerosis (MS) lesions in the brain and spinal cord. The number and volume of lesions have been used to evaluate MS disease burden, to track the progression of the disease and to evaluate the effect of new pharmaceuticals in clinical trials. Accurate identification of MS lesions in MR images is extremely difficult due to variability in lesion location, size and shape in addition to anatomical variability between subjects. Since manual segmentation requires expert knowledge, is time consuming and is subject to intra-and interexpert variability, many methods have been proposed to automatically segment lesions.The objective of this study was to carry out a systematic review of the literature to evaluate the state of the art in automated multiple sclerosis lesion segmentation. From 1240 hits found initially with PubMed and Google scholar, our selection criteria identified 80 papers that described an automatic lesion segmentation procedure applied to MS. Only 47 of these included quantitative validation with at least one realistic image. In this paper, we describe the complexity of lesion segmentation, classify the automatic MS lesion segmentation methods found, and review the validation methods applied in each of the papers reviewed. Although many segmentation solutions have been proposed, including some with promising results using MRI data obtained on small groups of patients, no single method is widely employed due to performance issues related to the high variability of MS lesion appearance and differences in image acquisition. The challenge remains to provide segmentation techniques that work in all cases regardless of the type of MS, duration of the disease, or MRI protocol, and this within a comprehensive, standardized validation framework. MS lesion segmentation remains an open problem.

show abstract

Section: Introductionmentioning

confidence: 99%

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

García-Lorenzo

Francis

Narayanan

et al. 2013

Medical Image Analysis

316

268

View full text Add to dashboard Cite

show abstract

“…31,35 In analyzing the effects of NAbs, some authors have used the ever positive, always positive method, in which patients who were ever NAb-positive are compared to persistently NAb-negative subjects. 19,[21][22][23][24][25] Other studies use the so-called once positive, always positive method, in which only observations after the patient has become NAb-positive (often defined as two consecutive positive tiers) are compared to observations in NAb-negative subjects. [14][15][16]20,29,31 Each of these methods fails to account for subjects who revert to NAb-negative status after becoming NAb-positive.…”

Section: -49mentioning

confidence: 99%

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

et al. 2007

View full text Add to dashboard Cite

Abstract-The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFN␤) while on this therapy for multiple sclerosis (MS) is assessed. On the basis of Class II and III evidence, it is concluded that treatment of patients with MS with IFN␤ (Avonex, Betaseron, or Rebif) is associated with the production of NAbs (Level A). NAbs in the serum are probably associated with a reduction in the radiographic and clinical effectiveness of IFN␤ treatment (Level B). In addition, the rate of NAb production is probably less with IFN␤-1a treatment than with IFN␤-1b treatment, although the magnitude and persistence of this difference is difficult to determine (Level B). Finally, it is probable that there is a difference in seroprevalence due to variability in the dose of IFN␤ injected or in the frequency or route of its administration (Level B). Regardless of the explanation, it seems clear that IFN␤-1a (as it is currently formulated for IM injection) is less immunogenic than the current IFN␤ preparations (either IFN␤-1a or IFN␤-1b) given multiple times per week subcutaneously (Level A). However, because NAbs disappear in some patients even with continued IFN␤ treatment (especially in patients with low titers), the persistence of this difference is difficult to determine (Level B). Although the finding of sustained high-titer NAbs (Ͼ100 to 200 NU/mL) is associated with a reduction in the therapeutic effects of IFN␤ on radiographic and clinical measures of MS disease activity, there is insufficient information on the utilization of NAb testing to provide specific recommendations regarding when to test, which test to use, how many tests are necessary, or which cutoff titer to apply (Level U).

show abstract

“…There was a significant effect of treatment on relapse rates, and MRI measures including lesion load, and new or enlarging T2 lesions. 53 A subgroup analysis suggested that maximal benefit with IFNβ-1a treatment in SPMS was seen in patients who continued to experience relapses, tending to confirm the outcomes of the European and North American IFNβ-1b studies.…”

Section: Dovepressmentioning

confidence: 85%

Early stage and long term treatment of multiple sclerosis with interferon-β

Panitch¹

2009

BTT

View full text Add to dashboard Cite

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

Abstract: Interferon-beta-1a used in SPMS showed significant effects on all MRI measures, particularly in patients with relapses in the 2 years before the study.

Cited by 281 publications

References 23 publications

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

Early stage and long term treatment of multiple sclerosis with interferon-β

Contact Info

Product

Resources

About

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

Abstract: Interferon-beta-1a used in SPMS showed significant effects on all MRI measures, particularly in patients with relapses in the 2 years before the study.

Cited by 281 publications

References 23 publications

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

Early stage and long term treatment of multiple sclerosis with interferon-&beta;

Contact Info

Product

Resources

About

Early stage and long term treatment of multiple sclerosis with interferon-β